Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Combination therapy, Translational Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Lymphoid Malignancies, Biological Processes
The 26S proteasome consists of two major subcomplexes: a 19S regulatory particle (RP) that is responsible for unfolding and translocating ubiquitinylated substrates into the inner chamber of a 20S core particle (CP) that hydrolyzes substrates. PSMC2 belongs to the 19S heterohexameric AAA-ATPase ring of the 19S RP. Gene expression profiles from bone marrow CD138+ cells of MM patients enrolled on the phase III APEX trial revealed that PSMC2 overexpression correlated with reduced response to bortezomib therapy as well as inferior progression-free and OS (Median OS for PSMC2 high vs. PSMC2 low 300 days vs. 625 days n=380, Kaplan-Meier (KM) curves significant by log-rank test with p=7x10-6) Similarly, results from the MMRF CoMMpass study demonstrated that PSMC2 overexpression correlated with reduced OS (Median OS for PSMC2 high v low 1300 days vs. not reached, n=221 Kaplan-Meier (KM) curves significant by log-rank test with p=0.014). Strikingly, PSMC2 copy number was increased in tumor cells from nearly 40% of MM patients compared to normal controls.
Lentiviral-engineered overexpression of PSMC2 in MM cell lines increased proteasome activity and promoted bortezomib (Btz)-resistance (LD50 of 10 nM vs. 6 nM in U266 overexpressed vs. vector control cells respectively, LD50 of 9 nM vs. 6 nM in ARH77 overexpressed vs. vector controls respectively, PSMC2 effect significant with p<0.0001 by two-way ANOVA). Upon Btz challenge, PSMC2-overexpressing cells suppressed induction of the endoplasmic reticulum (ER) chaperone GRP78/BiP, reduced activation of the stress marker XBP-1 and blocked the unfolded protein response, relative to pLKO vector-transduced controls. We then performed a high-throughput pharmacologic screen to identify synthetic lethal interactions specific to PSMC2-overexpressing MM cell, identifying inhibitors that targeted the ER stress response, including inhibitors of HSP90, inositol-requiring enzyme 1a and p97/VCP. p97 is a key ATPase that interacts with ERAD transport channels to unfold, translocate and deliver ubiquitinylated substrates to ER-bound proteasomes. Subcellular fractionation and co-immunoprecipitation experiments indicated that PSMC2 physically interacts with ER-associated p97 to facilitate ERAD.
To target this interaction therapeutically, we cotreated PI-exposed MM patient cells with Btz and the ATP-competitive p97 inhibitor CB-5339 (CB), revealing synergistic effects (Btz LD50 2.5 nM vs. 7.5 nM, 2 nM vs 8 nM, 2 vs. 8 nM for patient samples treated with the first two patients treated with 0 or 100 nM CB and the third patient treated with 0 and 50 nM CB, p< 0.0001 for CB effect by two-way ANOVA testing). CB co-treatment with Btz reduced the growth of aggressive PSMC2 overexpressing myeloma xenografts in murine models and significantly extended OS (median OS 24 days CB/Btz vs 19-20 days for vehicle, Btz or CB treated, Kaplan-Meier curves with p=0.0014 by log-rank test). Importantly, CB exhibits a favorable side effect profile as monotherapy in early phase AML clinical trials. Taken together, we have identified a prognostic role for PSMC2 and revealed a novel mechanism of Btz tolerance that can be therapeutically exploited to overcome chemoresistance.
Disclosures: Malek: janssen: Consultancy, Speakers Bureau; BMS: Consultancy; medpacto: Research Funding; Adaptive Bio: Consultancy.